United States Genetic Testing Market to Reach USD 54.21 Billion by 2033, Driven by Personalized Medicine and Technological Innovations | DataM Intelligence

The Global Genetic Testing Market size reached US$14.72 billion in 2024 and is expected to reach US$54.21 billion by 2033, growing at a CAGR of 15.4% during the forecast period 2025-2033, according to the DataM Intelligence report.

This growth is driven by rising demand for personalized medicine, early disease detection, and advances in genomic technologies that enhance testing accuracy and speed. Expanding applications in oncology, rare diseases, and pharmacogenomics further propel market expansion. Increasing awareness and adoption of genetic testing in healthcare systems worldwide support sustained growth. Additionally, decreasing costs and technological innovations make genetic testing more accessible to a broader population.

United States: Key Industry Developments

✅ November 2025: Increased FDA approval speed for next-generation sequencing (NGS) genetic tests facilitated faster market entry of oncology and rare disease panels, improving diagnostics and personalized treatment options.

✅ August 2025: Expansion of direct-to-consumer (DTC) genetic testing services empowered consumers with ancestry, health predisposition, and pharmacogenomics insights, with regulatory frameworks evolving to ensure data privacy and test accuracy.

✅ June 2025: Major players like 23andMe, Myriad Genetics, and Illumina launched AI-powered genomic analysis tools enhancing data interpretation accuracy and scale, driving faster clinical decision-making and research advancements.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/genetic-testing-market?ram

Japan: Key Industry Developments

✅ October 2025: Japan's Ministry of Health approved reimbursement expansion for hereditary cancer genetic tests in national insurance, increasing accessibility and adoption in clinical practice.

✅ July 2025: Collaborative research initiatives between pharmaceutical companies and genetic test providers promoted pharmacogenomics applications improving drug safety and efficacy for Japanese populations.

✅ Early 2025: Technological upgrades in laboratory infrastructure enabled more affordable and rapid whole-genome sequencing, supporting early disease detection and preventative healthcare.

Mergers and Acquisitions (2025):

✅ Major players such as Genentech Inc., Sorenson Genomics, Abbott Molecular, and Quest Diagnostics have engaged in strategic acquisitions to expand their product portfolios and geographic reach.

✅ The market size is estimated at USD 17.21 billion in 2025 and is projected to reach USD 93.17 billion by 2035, growing at an 18.4% CAGR. Growth drivers include rising prevalence of hereditary diseases, increased prenatal testing, and integration of AI and machine learning for enhanced diagnosis accuracy.

✅ Asia Pacific is predicted to capture 36% market share by 2035 due to expanding healthcare infrastructure and rising awareness, while North America continues to lead due to strong healthcare systems and technological innovations.

Growth Drivers:

-The global genetic testing market was valued at USD 14.59 billion in 2025, with projections to reach USD 91.30 billion by 2034, growing at a CAGR of 22.6%.

-Rising demand for personalized medicine, early disease detection, and advancements in genomic technologies are key growth drivers.

-North America dominated the market in 2024 with the largest revenue share due to technological advancements and increased genetic disorder awareness.

-The Asia-Pacific region is expected to witness the fastest CAGR during the forecast period, fueled by expanding healthcare infrastructure and rising prevalence of genetic disorders.

-Next-generation sequencing (NGS) technologies lead the market, with significant growth in array technologies and expanding applications in health and wellness predisposition/risk detection and genetic disease carrier status identification.

Market Segmentation Analysis:

-By Type

Carrier Testing: Used to identify carriers of genetic mutations, especially for hereditary diseases.

Diagnostic Testing: The largest segment, used for early diagnosis and confirmation of genetic disorders, holding significant market share.

Forensic Testing: Applied in legal and criminal investigations, growing with advancements in forensic technologies.

New-born Screening: Increasingly adopted globally for early detection of congenital conditions in infants.

Others: Include prenatal testing, pharmacogenomics, and predictive testing.

-By Sample

Blood samples dominate due to ease of collection and high DNA yield.

Saliva samples are growing in popularity for non-invasive collection and convenience.

Hair samples are less common but used in specific forensic and ancestry testing.

Others include amniotic fluid, buccal swabs, and tissue samples.

-By Technology

Biochemical Genetic Testing: Traditional tests that analyze biochemical markers, enzymes, and metabolites.

Chromosomal Genetic Testing: Includes karyotyping and FISH for detecting chromosomal abnormalities.

Others: Encompass next-generation sequencing (NGS), array CGH, PCR, and emerging CRISPR-based technologies.

-By Disease

Cancer: Largest application segment, constituting about 25% market share by 2035, driven by hereditary cancers and personalized medicine.

Alzheimer's Disease: Growing focus for early diagnosis and risk prediction.

Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, and Rare Diseases: Significant segments for diagnostic and carrier testing due to high unmet medical needs.

Others: Include various genetic and multifactorial diseases.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=genetic-testing-market?ram (Purchase 2 or more Reports and get 50% Discount)

Regional Insights:

United States

-The U.S. genetic testing market was valued at approximately USD 9.7 billion in 2024 and is projected to grow at a CAGR of about 20-23% from 2025 to 2030.

-Growth drivers include rising adoption of personalized and precision medicine, advances in next-generation sequencing (NGS) technologies, and increasing awareness of hereditary diseases.

-Expansion of direct-to-consumer genetic testing kits and broad application in oncology, prenatal testing, and pharmacogenomics contribute to market growth.

Major companies include Illumina, Myriad Genetics, 23andMe, and Guardant Health.

Japan

-Japan's genetic testing market is smaller than the U.S. but growing rapidly, estimated near USD 1.2 billion in 2024 with a CAGR of ~15-17% over the next decade.

-Emphasis on preventive healthcare, aging population, and government support for genomic medicine programs accelerate adoption.

-Clinical genetics services in hospitals and diagnostic labs are increasing, with strong government initiatives to integrate genomic data into healthcare.

Europe

-Europe accounts for a significant share with an estimated market size of approximately USD 4 billion in 2024, growing at a CAGR of about 11-13% through 2030.

-Countries like the UK, Germany, and France lead Europe's market due to established healthcare infrastructure and investments in genomic research.

-Regulatory frameworks like GDPR impact genetic data handling, promoting secure and privacy-compliant testing.

-Oncology and prenatal genetic testing are prominent segments fueling demand.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/genetic-testing-market?ram

Competitive Landscape:

According to DataM Intelligence, the Genetic Testing Market is moderately consolidated, with leading global biotechnology and diagnostics companies leveraging technological advancements, strategic partnerships, and expanding their portfolio to meet growing demand in personalized medicine, disease diagnosis, and preventive healthcare.

Key Players
Abbott Laboratories | Bio-Rad Laboratories Inc. | Illumina Inc. | Myriad Genetics Inc. | Danaher Corporation | Quest Diagnostics Incorporated | MedGenome | LabCorp | 3billion, Inc. | Blueprint Genetics

Key Highlights (Top 5 Key Players)

-Illumina Inc. leads the market with an estimated 27% share, driven by innovations in next-generation sequencing (NGS) and expansions in clinical and consumer genomics markets.

-Danaher Corporation holds approximately 15% market share through its comprehensive genetic testing platforms and acquisitions enhancing diagnostics capabilities.

-Abbott Laboratories accounts for around 12% share, supported by integrated point-of-care genetic testing systems and significant investments in molecular diagnostics.

-Quest Diagnostics Incorporated controls nearly 10%, emphasizing broad laboratory testing services combined with cutting-edge genetic test offerings.

-Myriad Genetics Inc. captures about 8%, known for specialty genetic testing in oncology and hereditary diseases, supported by ongoing R&D and strategic collaborations.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.